National team head coach Igor Stimac on Sunday hailed Sunil Chhetri, saying the talismanic captain was one of those who "glorified" Indian football with his dedication in the 15 years of his illustrious career.
The 35-year-old Chhetri on Friday became only the second Indian after legendary Bhaichung Bhutia to complete 15 years in Indian jersey. He made his debut in 2005 against Pakistan in Quetta in a friendly match. He had scored in the 1-1 drawn game.
According to Stimac, Chhetri is someone who always runs the extra yard, breaks some more sweat during training sessions, which encourages youngsters to emulate him.
"I see him as someone who always pushes the bar in training and never compromises with the regime. He drives the team and he is the character who defines the team. Numerous characters have glorified the Indian football history and he's definitely one of them who have made his country proud," the Croatian tactician said.
"Dedicated, workaholic and team man -- those are some of the attributes which define Sunil Chhetri," he said in a release issued by the All India Football Federation.
The former Croatian World Cup star, who took charge of the national team last year, recalled seeing Chhetri during the preparatory camp ahead of the King's Cup 2019 -- his maiden assignment with the Blue Tigers.
He pointed out that despite being the senior-most member of the team, Chhetri toiled maximum to achieve positive results after the heartbreak in AFC Asian Cup.
"When I first saw him last year, they were back to the National Team camp after a long gap following the AFC Asian Cup. A few boys were new but the fire under his belly probably was more than anyone else. That's the secret of his long career. Congratulations!" Stimac said.
Former India coach Sukhwinder Singh, who guided the Indians in that match against Pakistan in 2005, had said that he was not sure of Chhetri's credibility then.
"I needed someone who had the trickery, didn't have the fear, and had to be quick. Honestly, Sunil wasn't in my mind at all. He wasn't my first option. I had my doubts," Sukhwinder had said.
"I saw him maturing in JCT and there were flashes of what he could do in future. I still remember his hunger. In 19 years of my coaching career, I haven't seen anyone as dedicated as Sunil. He remained undaunted and was never willing to shy away from working hard.
"Shouldering the responsibility for 15 years demands discipline and he keeps it above everything else.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.